Rivaroxaban CAS 366789-02-8 Factor Xa Inhibitor for Stroke and VTE Prevention hfd
TDS 13 Inquiries
366789-02-8
Reagent Grade
99%
qingdao
//
5g, 25g, 100g, 500g
2026-09-19
Medetomidine,Medetomidine hydrochloride,D-Lysergic Acid Methyl Ester,SR17018,Fluralaner,GS-441524
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceRivaroxaban is a highly potent and selective, direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM).
Rivaroxaban is a monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-chlorothiophene-2-carboxylic acid with the amino group of 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one. An anticoagulant used for prophylaxis of venous thromboembolism in patients with knee or hip replacement surgery. It has a role as an anticoagulant and an EC 3.4.21.6 (coagulation factor Xa) inhibitor. It is a member of thiophenes, an organochlorine compound, an oxazolidinone, a member of morpholines, a lactam, an aromatic amide and a monocarboxylic acid amide.|Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011.|Rivaroxaban is a Factor Xa Inhibitor. The mechanism of action of rivaroxaban is as a Factor Xa Inhibitor.|Edoxaban is an oral, small molecule inhibitor of factor Xa which is used as an anticoagulant to decrease the risk of venous thromboses, systemic embolization and stroke in patients with atrial fibrillation, and as treatment of deep vein thrombosis and pulmonary embolism to prevent thrombotic complications. Edoxaban has been linked to a low rate of serum aminotransferase elevations during therapy, but has not been implicated in cases of clinically apparent acute liver injury.|Rivaroxaban is a recently developed oral anticoagulant and direct factor Xa inhibitor which is used in the prevention of stroke and venous embolism in patients with chronic atrial fibrillation, as well as treatment and prevention of deep venous thromboses and pulmonary embolism. Rivaroxaban has been associated with a low rate of serum enzyme elevations during treatment and with rare instances of clinically apparent liver injury with jaundice.|Rivaroxaban is an orally bioavailable oxazolidinone derivative and direct inhibitor of the coagulation factor Xa with anticoagulant activity. Upon oral administration, rivaroxaban selectively binds to both free factor Xa and factor Xa bound in the prothrombinase complex. This interferes with the conversion of prothrombin (factor II) to thrombin and eventually prevents the formation of cross-linked fibrin clots. Rivaroxaban does not affect existing thrombin levels.|A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.Certificates-
TDS
Basic Info-
Product Name:
Rivaroxaban
Other Name:2-Thiophenecarboxamide,5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-5-oxazolidinyl]methyl]-;5-Chloro-N-[[(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-5-oxazolidinyl]methyl]-2-thiophenecarboxamide;Rivaroxaban;BAY 59-7939;5-Chloro-N-[[(S)-3-(4-(3-oxomorpholin-4-yl)phenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]-thiophene-2-carboxamide;Xarelto;5-Chloro-N-[[(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl]methyl]-2-thiophenecarboxamide;5-Chloro-N-([(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl]-methyl)-2-thiophenecarboxamide;(S)-Rivaroxaban;869880-21-7;931117-62-3;1807854-46-1
CAS No.:366789-02-8
Molecular Formula:C19H18ClN3O5S
InChIKeys:InChIKey=KGFYHTZWPPHNLQ-AWEZNQCLSA-N
Molecular Weight:435.88
Exact Mass:435.88
EC Number:1308068-626-2
UNII:9NDF7JZ4M3
DSSTox ID:DTXSID3057723
NCI Thesaurus Code:C77995
Color/Form:White to yellowish powder
ATC Code:B01AF01|B - Blood and blood forming organs
Categories:
Characteristics-
PSA:
116
XLogP3:2.5
Appearance:1
Density:1.5±0.1 g/cm3
Melting Point:230 °C
Boiling Point:732.6°C at 760 mmHg
Flash Point:396.9±32.9 °C
Refractive Index:1.633
Water Solubility:Slightly soluble in organic solvents (e.g. acetone, polyethylene glycol 400) and is pratically insoluble in water and aqueous media
Storage Conditions:Refrigerator
Vapor Pressure:6.66X10-16 mm Hg at 25 deg C (est)
Odor:Odorless
Henrys Law Constant:Henry's Law constant = 9,46X10-85 atm-cu m/mol at 25 °C (est)
Hazard IdentificationClassification of the substance or mixture
Hazardous to the aquatic environment, long-term (Chronic) - Category Chronic 2
GHS label elements, including precautionary statements
Pictogram(s)
Signal word No signal word
Hazard statement(s) H411 Toxic to aquatic life with long lasting effects
Precautionary statement(s) Prevention P273 Avoid release to the environment.
Response P391 Collect spillage.
Storage none
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Medetomidine,Medetomidine hydrochloride,D-Lysergic Acid Methyl Ester,SR17018,Fluralaner,GS-441524
-
Location:
RONGSHENG BEIYUANDAJIE 9, LICHENG DISTRICT,JINAN, SHANDONG CHINA
-
Payment Terms:
TT against copy of documents,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
7
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
11-50
-
Year of Establishment:
2022
-
-
Inquiry History13 Inquiries
Country Product Purchase Quantity Date Posted
India
Rivaroxaban
100.00 KG Jan 8, 2026
India
Rivaroxaban
200.00 KG Aug 17, 2026
India
Rivaroxaban
1.00 KG Mar 8, 2026
Pakistan
Rivaroxaban
1.00 KG Jan 23, 2026
India
Riveroxaban
1 MG Dec 22, 2025
India
Rivaroxaban
500 G Aug 11, 2026
India
Nickel Oxide Sulphate
1.00 KG May 11, 2026
India
Rivaroxaban
1.00 KG Mar 18, 2026
India
Rivaroxaban
1.00 KG Mar 11, 2026
India
Rivaroxaban
500.00 KG Feb 2, 2026
India
Rivoraxaban IP
10.00 KG Jan 22, 2026
India
Rivaroxaban
15 KG Jul 29, 2025
Pakistan
Febuxostat
800.00 KG Aug 4, 2026 Post an enquiry for this product